课题基金 / 基金详情

COCAINE THERAPEUTIC: PD2005 DOPAMINE TRANSPORT INHIBITOR

COCAINE THERAPEUTIC: PD2005 DOPAMINE TRANSPORT INHIBITOR
可卡因治疗:PD2005 多巴胺转运抑制剂
批准号:
6785636
负责人:
FRANK P ZEMLAN
金额:
$13.65万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2004
资助国家:
美国
项目状态:
已结题
起止时间:
2004-04-01 至 2006-03-31

项目摘要

项目成果

FRANK P ZEMLAN的其他基金

相似基金

相关文献

中文摘要
翻译
描述(由申请者提供):美国国家药物滥用研究所表示:“NIDA的首要研究重点是找到一种药物来阻断或大大降低可卡因的影响,作为综合治疗计划的一部分。”目前快速通道第一阶段应用的目的是继续开发我们专有的多巴胺(DA)运输抑制剂PD2005,作为可卡因治疗药物。 广泛的研究表明,可卡因的滥用潜力是由于大脑中DA转运体的直接结合和抑制。虽然大多数抑制DA转运体的药物都是滥用药物(如可卡因、苯丙胺),但苯妥拉平是个例外。苯妥拉平在40年前被FDA批准用于治疗帕金森氏症,并未被滥用。不幸的是,苯妥拉平有显著的抗胆碱能M1副作用,使其不能用作可卡因治疗药物。合成了一种苯并托品类似物,PD2005,它没有高亲和力的M1结合,但对DA转运体有高亲和力。此外,PD2005的作用起效缓慢,可最大限度地减少滥用潜力,PD2005的作用持续时间长,允许实际的剂量制度,而且与可卡因不同,PD2005不是在猴子身上自行给药,表明很少或根本没有滥用潜力。拟议的第一阶段研究将确定PD2005的预处理是否会阻止猴子的可卡因自我给药--这是可卡因潜在治疗的关键特性。我们建议: 具体目的:优化目前PD2005工业化生产的合成方法,在良好的实验室操作条件下合成PD2005。FDA要求成功生产的GLP药物用于拟议的快速通道第二阶段研究。 具体目标1B:确定PD2005是否抑制猴子的可卡因自身给药剂量-反应曲线。具体目标1C。通过测定PD2005对食物强化维持的猴子的操作剂反应的影响,确定PD2005是否选择性地抑制可卡因的剂量-反应曲线。
英文摘要
DESCRIPTION (provided by applicant): The National Institute of Drug Abuse has indicated, "NIDA's top research priority is to find a medication to block or greatly reduce the effects of cocaine to be used as part of a comprehensive treatment program." The purpose of the present FAST TRACK Phase 1 application is to continue development of our proprietary dopamine (DA) transport inhibitor, PD2005, as a cocaine therapeutic. Extensive research shows that the abuse potential of cocaine is due to direct binding and inhibition of the DA transporter in brain. While most drugs that inhibit the DA transporter are drugs of abuse (e.g. cocaine, amphetamine) benztropine is the exception. Benztropine was FDA approved 40 years ago for treating Parkinson's Disease and is not abused. Unfortunately, benztropine has significant anticholinergic M1 side effects that preclude its use as a cocaine therapeutic. A benztropine analog, PD2005, has been synthesized that has no high affinity M1 binding while demonstrating high affinity for the DA transporter. Further, PD2005 has a slow onset of action that minimizes abuse potential, PD2005 has a long duration of action which allows practical dosing regimes, and PD2005, unlike cocaine, is not self-administered in monkeys indicating little or no abuse potential. Proposed Phase 1 studies will determine if pretreatment with PD2005 blocks cocaine self-administration in monkeys - a critical property for potential cocaine therapeutic. We propose: Specific AimlA: Optimize the current PD2005 synthetic method for commercial production and synthesize PD2005 under Good Laboratory Practice Conditions. Succesfully manufactured GLP drug is required by FDA for proposed FAST TRACK Phase 2 studies. Specific Aim 1B: Determine if PD2005 depresses the cocaine self-administration dose-response curve in monkeys. Specific Aim 1C. Determine if PD2005 selectively depresses the cocaine dose-response curve by determining the effect of PD2005 pretreatment on operant responding in monkeys maintained by food reinforcement.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Serum C-tau Precition of Brain Damage in Mild TBI
  • 批准号:
    6689352
  • 项目类别:
  • 资助金额:
    $12.86万
  • 财政年份:
    2003
  • 负责人:
    FRANK P ZEMLAN
  • 依托单位:
Biomarker for Subarachnoid Hemorrhage
  • 批准号:
    6483618
  • 项目类别:
  • 资助金额:
    $12.81万
  • 财政年份:
    2002
  • 负责人:
    FRANK P ZEMLAN
  • 依托单位:
Melatonin Analog for Sleep Disorders
  • 批准号:
    6707905
  • 项目类别:
  • 资助金额:
    $50.43万
  • 财政年份:
    2002
  • 负责人:
    FRANK P ZEMLAN
  • 依托单位:
Melatonin Analog for Sleep Disorders
  • 批准号:
    6712083
  • 项目类别:
  • 资助金额:
    $46.32万
  • 财政年份:
    2002
  • 负责人:
    FRANK P ZEMLAN
  • 依托单位:
国内基金
海外基金
新型四环素类似物的优化设计、合成及神经保护作用研究
  • 批准号:
    20972011
  • 项目类别:
    面上项目
  • 资助金额:
    35.0万元
  • 批准年份:
    2009
  • 负责人:
    刘俊义
  • 依托单位: